PMS46 Cost-Utility Analysis of Certolizumab Pegol versus Alternative Tumor Necrosis Factor-Inhibitors, for the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Spain
Abstract
Authors
R. Villoro A. Hidalgo B. Ferro P. Talavera